Tissue factor associates with survival and regulates tumour progression in osteosarcoma
Chris Tieken
1
Einthoven Laboratory for Experimental Vascular Medicine, Department of Thrombosis and Hemostasis, Leiden University Medical Centre, Leiden, The Netherlands
,
Michiel C. Verboom
2
Department of Clinical Oncology, Leiden University Medical Centre, Leiden, The Netherlands
,
Wolfram Ruf
3
Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, USA
,
Hans Gelderblom
2
Department of Clinical Oncology, Leiden University Medical Centre, Leiden, The Netherlands
,
Judith V. M. G. Bovée
4
Department of Pathology, Leiden University Medical Centre, Leiden, The Netherlands
,
Pieter H. Reitsma
1
Einthoven Laboratory for Experimental Vascular Medicine, Department of Thrombosis and Hemostasis, Leiden University Medical Centre, Leiden, The Netherlands
,
Anne-Marie Cleton-Jansen
4
Department of Pathology, Leiden University Medical Centre, Leiden, The Netherlands
,
Henri H. Versteeg
1
Einthoven Laboratory for Experimental Vascular Medicine, Department of Thrombosis and Hemostasis, Leiden University Medical Centre, Leiden, The Netherlands
› Author AffiliationsFinancial Support: W. R. is funded by NIH grant HL60742, H. H. V. is funded by NWO grant 91710329.
Osteosarcoma is the most common primary malignant bone tumour. Patients often develop lung metastasis and have a poor prognosis despite extensive chemotherapy and surgical resections. Tissue Factor is associated with poor clinical outcome in a wide range of cancer types, and promotes angiogenesis and metastasis. The role of Tissue Factor in OS tumourigenesis is unknown. Fifty-three osteosarcoma pre-treatment biopsies and four osteosarcoma cell lines were evaluated for Tissue Factor expression, and a possible association with clinical parameters was investigated. Tissue Factor function was inhibited in an osteosarcoma cell line (143B) by shRNA knockdown or specific antibodies, and pro-tumourigenic gene expression, proliferation, matrigel invasion and transwell migration was examined. 143B cells were implanted in mice in the presence of Tissue Factor-blocking antibodies, and tumour volume, micro-vessel density and metastases in the lung were evaluated. Tissue Factor was highly expressed in 73.6 % of osteosarcoma biopsies, and expression associated significantly with disease-free survival. Tissue Factor was expressed in all four investigated cell lines. Tissue Factor was knocked down in 143B cells, which led to reduced expression of IL-8, CXCL-1, SNAIL and MMP2, but not MMP9. Tissue Factor knockdown or inhibition with antibodies reduced matrigel invasion. Tissue Factor antibodies limited 143B tumour growth in vivo, and resulted in decreased intra-tumoural micro-vessel density. Furthermore, lung metastasis from the primary tumour was significantly reduced. Thus, Tissue Factor expression in osteosarcoma reduces metastasis-free survival in patients, and increases pro-tumourigenic behaviour both in vitro and in vivo.
Supplementary Material to this article is available online at www.thrombosis-online.com.
2
van Oosterwijk JG,
Anninga JK,
Gelderblom H.
et al. Update on targets and novel treatment options for high-grade osteosarcoma and chondrosarcoma. Hematol Oncol Clin North Am 2013; 27: 1021-1048.
3
Glasser DB,
Lane JM,
Huvos AG.
et al. Survival, prognosis, and therapeutic response in osteogenic sarcoma. The Memorial Hospital experience. Cancer 1992; 69: 698-708.
4
McTiernan A,
Jinks RC,
Sydes MR.
et al. Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: a report from the European Osteosarcoma Intergroup. Eur J Cancer 2012; 48: 703-712.
5
Drake TA,
Morrissey JH,
Edgington TS.
Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am J Pathol 1989; 134: 1087-1097.
6
Yu JL,
May L,
Lhotak V.
et al. Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumour progression and angiogenesis. Blood 2005; 105: 1734-1741.
7
Rong Y,
Belozerov VE,
Tucker-Burden C.
et al. Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity. Cancer Res 2009; 69: 2540-2549.
8
Nitori N,
Ino Y,
Nakanishi Y.
et al. Prognostic significance of tissue factor in pancreatic ductal adenocarcinoma. Clin Cancer Res 2005; 11: 2531-2539.
10
Sawada M,
Miyake S,
Ohdama S.
et al. Expression of tissue factor in non-small-cell lung cancers and its relationship to metastasis. Br J Cancer 1999; 79: 472-477.
14
Kuijjer ML,
van den Akker BEWM,
Hilhorst R.
et al. Kinome and mRNA expression profiling of high-grade osteosarcoma cell lines implies Akt signalling as possible target for therapy. BMC Med Genomics 2014; 7: 4.
15
Yang J-S,
Lin C-W,
Hsieh Y-S.
et al. Selaginella tamariscina (Beauv.) possesses antimetastatic effects on human osteosarcoma cells by decreasing MMP-2 and MMP-9 secretions via p38 and Akt signalling pathways. Food Chem Toxicol 2013; 59: 801-807.
16
Miwa S,
Sugimoto N,
Yamamoto N.
et al. Caffeine induces apoptosis of osteosarcoma cells by inhibiting AKT/mTOR/S6K, NF-βB and MAPK pathways. Anticancer Res 2012; 32: 3643-3649.
17
Chen X,
Bahrami A,
Pappo A.
et al. Recurrent somatic structural variations contribute to tumourigenesis in pediatric osteosarcoma. Cell Rep 2014; 7: 104-112.
18
Ichikawa J,
Cole HA,
Magnussen RA.
et al. Thrombin induces osteosarcoma growth, a function inhibited by low molecular weight heparin in vitro and in vivo: Procoagulant nature of osteosarcoma. Cancer 2012; 118: 2494-2506.
19
Daubie V,
De Decker R,
Nicaise C.
et al. Osteosarcoma cell-calcium signalling through tissue factor-factor VIIa complex and factor Xa. FEBS Lett 2007; 581: 2611-2615.
20
Mohseny AB,
Szuhai K,
Romeo S.
et al. Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidisation and genomic loss of Cdkn2. J Pathol 2009; 219: 294-305.
21
Kocatürk B,
Van den Berg YW,
Tieken C.
et al. Alternatively spliced tissue factor promotes breast cancer growth in a α1 integrin-dependent manner. Proc Natl Acad Sci USA 2013; 110: 11517-11522.
22
Jessani N,
Humphrey M,
McDonald WH.
et al. Carcinoma and stromal enzyme activity profiles associated with breast tumour growth in vivo. Proc Natl Acad Sci USA 2004; 101: 13756-13761.
23
Tuominen VJ,
Ruotoistenmäki S,
Viitanen A.
et al. ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67. Breast Cancer Res 2010; 12: R56.
24
Mohseny AB,
Machado I,
Cai Y.
et al. Functional characterisation of osteosarcoma cell lines provides representative models to study the human disease. Lab Invest 2011; 91: 1195-1205.
25
Lauvrak SU,
Munthe E,
Kresse SH.
et al. Functional characterisation of osteosarcoma cell lines and identification of mRNAs and miRNAs associated with aggressive cancer phenotypes. Br J Cancer 2013; 109: 2228-2236.
26
van den Berg YW,
Osanto S,
Reitsma PH.
et al. The relationship between tissue factor and cancer progression: insights from bench and bedside. Blood 2012; 119: 924-932.
27
Hjortoe GM.
Tissue factor-factor VIIa-specific up-regulation of IL-8 expression in MDA-MB-231 cells is mediated by PAR-2 and results in increased cell migration. Blood 2004; 103: 3029-3037.
28
Yang H,
Zhang Y,
Zhou Z.
et al. Transcription factor Snai1–1 induces osteosarcoma invasion and metastasis by inhibiting E-cadherin expression. Oncol Lett 2014; 8: 193-197.
29
Poudel B,
Kim D-K,
Ki H-H.
et al. Downregulation of ERK signalling impairs U2OS osteosarcoma cell migration in collagen matrix by suppressing MMP9 production. Oncol Lett 2014; 7: 215-218.
31
Whelan JS,
Bielack SS,
Marina N.
et al. EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment. Ann Oncol 2015; 26: 407-414.
32
Chen D,
Zhang Y-J,
Zhu K.
et al. A systematic review of vascular endothelial growth factor expression as a biomarker of prognosis in patients with osteosarcoma. Tumour Biol 2013; 34: 1895-1899.
34
Altomare DF,
Rotelli MT,
Pentimone A.
et al. Tissue factor and vascular endothelial growth factor expression in colorectal cancer: relation with cancer recurrence. Colorectal Dis 2007; 9: 133-138.
37
Mu Y,
Zhang H,
Che L.
et al. Clinical significance of microRNA-183/Ezrin axis in judging the prognosis of patients with osteosarcoma. Med Oncol 2014; 31: 821.
38
Zhang H,
Yin Z,
Ning K.
et al. Prognostic value of microRNA-223/epithelial cell transforming sequence 2 signalling in patients with osteosarcoma. Hum Pathol 2014; 45: 1430-1436.
39
Anninga JK,
van de Vijver MJ,
Cleton-Jansen AM.
et al. Overexpression of the HER-2 oncogene does not play a role in high-grade osteosarcomas. Eur J Cancer 2004; 40: 963-970.
41
Schaffner F,
Versteeg HH,
Schillert A.
et al. Cooperation of tissue factor cytoplasmic domain and PAR2 signalling in breast cancer development. Blood 2010; 116: 6106-6113.
43
Morrow DA,
Murphy SA,
McCabe CH.
et al. Potent inhibition of thrombin with a monoclonal antibody against tissue factor (Sunol-cH36): results of the PROXIMATE-TIMI 27 trial. Eur Heart J 2005; 26: 682-688.
44
Gomes CMF,
Welling M,
Que I.
et al. Functional imaging of multidrug resistance in an orthotopic model of osteosarcoma using 99mTc-sestamibi. Eur J Nucl Med Mol Imaging 2007; 34: 1793-1803.
46
Dorfleutner A,
Hintermann E,
Tarui T.
et al. Cross-talk of integrin alpha3beta1 and tissue factor in cell migration. Mol Biol Cell Am Soc Cell Biol 2004; 15: 4416-4425.